NEW YORK – Fulgent Genetics and BioIQ announced Tuesday a partnership to identify variants of SARS-CoV-2, the virus that causes COVID-19, using next-generation sequencing.
BioIQ, an Atlanta-based diagnostic testing software company, will offer Fulgent's coronavirus genome sequencing assay on its software platform to its employer, government, and health plan customers to inform testing regimens, clinical treatment protocols, and vaccination strategies.
Financial and other terms of the deal were not disclosed.